TCM
HRMY icon

Teza Capital Management’s Harmony Biosciences HRMY Stock Holding History

Teza Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,416
Closed -$207K – 645
2023
Q4 		$207K Buy
+6,416
New +$179K 0.03% 497

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Teza Capital Management's HRMY Position: Q1 2024 in Review

Teza Capital Management sold out of Harmony Biosciences (HRMY) in Q1 2024, closing a stake of 6,416 shares — an estimated $207K sold.

Teza Capital Management first reported a position in HRMY in Q4 2023 and held it in 1 quarter. The position peaked at $207K in Q4 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Teza Capital Management reported no remaining Harmony Biosciences position as of Q1 2024 after selling out during the quarter.
  • Teza Capital Management sold 6,416 Harmony Biosciences shares in Q1 2024, an estimated $207K.
  • Teza Capital Management first reported a position in Harmony Biosciences in Q4 2023 and held it in 1 quarter.
  • Teza Capital Management's Harmony Biosciences position peaked at $207K in Q4 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Teza Capital Management's 13F filing for Q1 2024, filed 15 May 2024.